Company intelligence / Profile preview

UTR Therapeutics

New York, New York, USAutrtherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

UTR Therapeutics has submitted an IND application to the US FDA for its lead candidate UTRxM1-18 targeting c-MYC-driven cancers using a proprietary RNA-destabilizing approach. Preclinical data show high specificity and safety in targeting tumor cells with minimal effect on healthy cells. The company is advancing additional programs against MYCN, TEAD1/YAP1 for cancer as well as targets in obesity, MASH, and neurodegeneration

Therapeutic areas: OncologyEndocrinologyMetabolic DisordersNeurology
Modalities: RNA therapymRNA-based drugs
Industry: Biotech

Drug pipeline

9 assets

UTR-HER2-NSCLC-ex19del

Preclinical

8 more assets in the full pipeline.

Request access →

Partnerships

No major partnerships publicly disclosed as of June 2025

Beyond the preview

Go deeper on UTR Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UTR Therapeutics.

Explore the full profile